Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments
08:38am, Tuesday, 29'th Jul 2025
Sarepta Therapeutics shares jumped over 36% in premarket trading on Tuesday after the company said it had received US Food and Drug Administration (FDA) approval to restart shipments of its flagship g
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
07:21am, Tuesday, 29'th Jul 2025
Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and d
Sarepta resumes shipping of gene therapy Elevidys to patients who can walk
07:01am, Tuesday, 29'th Jul 2025
CNBC's Becky Quick reports on the latest news.
Sarepta Stock Just Soared 45%. Here's Why.
05:01am, Tuesday, 29'th Jul 2025
Shipments of the medicine were paused by request by the FDA, following safety concerns.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
06:58pm, Monday, 28'th Jul 2025
NEW YORK , July 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and J
SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) collapse again – this time, shares closed down
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA
US FDA recommends removal of hold on Sarepta's Elevidys in some patients
04:59pm, Monday, 28'th Jul 2025
The U.S. Food and Drug Administration said on Monday it is recommending the removal of the hold placed on Sarepta Therapeutics' gene therapy Elevidys for patients with a rare muscular disorder who can
Investors can contact the law firm at no cost to learn more about recovering their losses
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SRPT
03:29pm, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violatio
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). S
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:36am, Monday, 28'th Jul 2025
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarep
